Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant.

MLA

Tyler, Timothy, et al. “Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant.” Clinical Pharmacology in Drug Development, vol. 11, no. 12, Dec. 2022, pp. 1405–18. EBSCOhost, https://doi.org/10.1002/cpdd.1183.

APA

Tyler, T., Schultz, A., Venturini, A., Giuliano, C., Bernareggi, A., Spezia, R., Voisin, D., & Stella, V. (2022). Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant. Clinical Pharmacology in Drug Development, 11(12), 1405–1418. https://doi.org/10.1002/cpdd.1183

Chicago

Tyler, Timothy, Armin Schultz, Alessio Venturini, Claudio Giuliano, Alberto Bernareggi, Riccardo Spezia, Daniel Voisin, and Valentino Stella. 2022. “Challenges in the Development of Intravenous Neurokinin‐1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose‐Finding, Phase 1 Study of Intravenous Fosnetupitant.” Clinical Pharmacology in Drug Development 11 (12): 1405–18. doi:10.1002/cpdd.1183.